Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Receivables for 10 consecutive years, with $47.5 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 30.66% to $47.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.5 million through Dec 2025, up 30.66% year-over-year, with the annual reading at $47.5 million for FY2025, 30.66% up from the prior year.
  • Receivables for Q4 2025 was $47.5 million at Akebia Therapeutics, down from $66.2 million in the prior quarter.
  • The five-year high for Receivables was $138.6 million in Q2 2022, with the low at $19.1 million in Q1 2023.
  • Average Receivables over 5 years is $46.3 million, with a median of $36.7 million recorded in 2021.
  • The sharpest move saw Receivables soared 2818.04% in 2021, then plummeted 85.88% in 2023.
  • Over 5 years, Receivables stood at $70.7 million in 2021, then tumbled by 40.31% to $42.2 million in 2022, then grew by 1.04% to $42.6 million in 2023, then fell by 14.65% to $36.4 million in 2024, then soared by 30.66% to $47.5 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $47.5 million, $66.2 million, and $73.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.